Search
Enfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalEnfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake … The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseMethylphenobarbital
go.drugbank.com/drugs/DB00849ApprovedA barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.
Cerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency. … [L51329] CLN2 is a predominantly pediatric-onset neurodegenerative disease caused by a deficiency in the lysosomal enzyme TPP1, leading to progressive impairment in motor and cognitive function.
Carbidopa
go.drugbank.com/drugs/DB00190ApprovedInvestigational[L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination … Due to its activity, carbidopa is always administered concomitantly with [levodopa].
Mixtures: DOPADEX SR 50 MG/200 MG UZATILMIŞ SALIMLI TABLET,100 TB, DOPADEX SR 25 MG/100 MG UZATILMIŞ SALIMLI TABLET ,100 TBNylidrin
go.drugbank.com/drugs/DB06152ApprovedWithdrawnNylidrin is utilized to treat several disorders that may benefit from increased blood flow (for example, certain mental disorders, blood vessel disease due to diabetes, frostbite, night leg cramps, and … This medication works by dilating (widening) blood vessels to help increase blood flow (improving circulation) throughout the body, including the extremities and central nervous system.
Lemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigational[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … [suvorexant]) act to counteract inappropriate wakefulness.
Tamoxifen
go.drugbank.com/drugs/DB00675ApprovedInvestigational[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. … Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.
Sodium iodide
go.drugbank.com/drugs/DB11119ApprovedInvestigationalSodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition [L2065] but is more commonly used in veterinary medicine. … Radiolabelled compound, [DB09293], is used as a diagnostic tool to evaluate thyroid function and morphology.
Mixtures: Micro+ Te PediatricNaltrexone
go.drugbank.com/drugs/DB00704ApprovedInvestigationalVet approvedThe FDA has approved naltrexone for the treatment of alcohol dependence. … It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Heterocyclic Compounds with 4 or More RingsConcizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigationalConcizumab therefore provides an important treatment option for patients who have developed inhibitors to standard clotting factor replacement therapy. … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.